U.S. Health Secretary Robert F. Kennedy Jr.'s recent dismissal of all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP) has triggered a strong backlash from vaccine experts. The ousted panelists warn that the abrupt shakeup may undermine public health, reduce access to lifesaving vaccines, and increase the risk of preventable disease outbreaks.
Kennedy, a longtime vaccine skeptic, replaced the committee with eight new appointees, some of whom have publicly questioned vaccine safety. The decision was made just two days after the firings on June 9, 2025. In a joint article published in the Journal of the American Medical Association (JAMA), the former ACIP members expressed alarm over what they described as a destabilizing and unjustified overhaul.
They argue that the move, along with cuts to CDC immunization staff, weakens the national vaccine program and threatens decades of progress. “These decisions, made without clear rationale, may roll back the achievements of U.S. immunization policy,” the experts wrote. They emphasized the potential risk to public trust and the safety of families across the country.
Kennedy claimed the firings were necessary to eliminate alleged conflicts of interest among the previous panel members, many of whom were appointed during the Biden administration. However, he provided no evidence of specific misconduct or bias.
Health professionals and scientists warn that politicizing vaccine oversight could erode confidence in health authorities and negatively impact vaccine uptake. The Department of Health and Human Services has not yet responded to media inquiries regarding the controversy.
Kennedy’s sweeping changes mark a significant shift in U.S. health policy and come amid growing concerns over misinformation and vaccine hesitancy.


Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Trump Bans CNN, MS NOW and Politico From White House
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children
Australia Tightens Student Visa Rules, Targets Migration Cut by 2028
Pezeshkian Says US Must Choose When Iran War Ends
China Reviews Broadcom Switch Use in State Data Centres
FDA Names Permanent Drug and Biologics Center Chiefs
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial
France Defends Netanyahu Airspace Clearance Despite ICC Warrant
North Korea Rejects Nuclear Test Warning, Calls Nuclear Status Irreversible
FAA Allows Boeing to Sell 35 More 777F Freighters Beyond 2028
Nvidia-Groq AI Chip Deal Faces U.S. Antitrust Probe
Trump, Xi Focus on Trade and AI at White House Summit
Synthetic data could ease people’s concerns about privacy breaches. But who gets to create it?
Netanyahu’s Brief US Trip Highlights Strains With Trump 



